

Inventor  
Search

6/5/1 (Item 1 from file: 350)  
DIALOG(R) File 350: Derwent WPIX  
(c) 2003 Thomson Derwent. All rts. reserv.

012784516  
WPI Acc No: 1999-590742/199950  
XRAM Acc No: C99-172446  
XRPX Acc No: N99-435716

**Augmenting damaged dermal, subcutaneous and vocal cord tissue**

Patent Assignee: GERIGENE MEDICAL CORP (GERI-N); KELLER G S (KELL-I)

Inventor: **KELLER G S** ; KLEINSEK D A

Number of Countries: 081 Number of Patents: 002

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 9943270	A1	19990902	WO 98US3538	A	19980224	199950 B
AU 9866649	A	19990915	AU 9866649	A	19980224	200004
			WO 98US3538	A	19980224	

Priority Applications (No Type Date): WO 98US3538 A 19980224

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

WO 9943270 A1 E 44 A61F-002/00

Designated States (National): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU  
CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR  
LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM  
TR TT UA UG US UZ VN YU ZW

Designated States (Regional): AT BE CH DE DK EA ES FI FR GB GH GM GR IE  
IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW

AU 9866649 A A61F-002/00 Based on patent WO 9943270

Abstract (Basic): WO 9943270 A1

NOVELTY - A method for corrective surgery in a human comprises: (a) retrieving viable cells from the subject; (b) culturing the viable cells in vitro; and (c) placing the in vitro cultured cells into a tissue of the subject. The tissue is located in a position subjacent to the defect to be rectified.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) an in vitro produced extra-cellular matrix composition, which is either substantially pure or combined with cells embedded in the matrix and is obtained from the process comprising: (a) culturing cells in vitro in a culture vessel for a time sufficient for the cells to produce extracellular matrix; (b) separating the extra-cellular matrix from the culture vessel and in addition, if the composition is pure, separating the extra-cellular matrix produced by the cultured cells from such cells; and (c) collecting the extra-cellular matrix; (2) a method for the long-term augmentation of subcutaneous or dermal tissue in a human subject which comprises: (a) providing a suspension of autologous, passage dermal, fibroblasts, free of immunogenic proteins; (b) identifying a defect that is susceptible to amelioration by augmentation of the sub-adjacent subcutaneous or dermal tissue; and (c) injecting an effective volume of the suspension into the sub-adjacent tissue so that the tissue is augmented; and (3) a device for repairing a dermal defect in a subject comprising: (a) a hypodermic syringe having a syringe chamber, a piston disposed therein, and an orifice communicating with the chamber; (b) a suspension comprising: dermal fibroblasts derived from the subject, the fibroblasts being free of cells other than fibroblasts and free of proteins that are immunogenic in the subject, and a carrier solution, the suspension being disposed in the chamber; and (c) a hypodermic needle affixed to the orifice.

USE - The process is used to treat a defect selected from a stretch mark, wrinkle, depressed scar, cutaneous depression, hypoplasia of the lip, prominent nasolabial fold, prominent melolabial fold, and scarring from acne vulgarism. Alternatively, the defect is present in the **vocal** cord of the subject, and the autologous in vitro cultured cells are placed in a site of the **vocal** cord selected from a scar, Reinke's space, a muscle of the **vocal** cord, and the lamina propria (all claimed).

pp; 44 DwgNo 0/0

Title Terms: AUGMENT; DAMAGE; DERMAL; SUBCUTANEOUS; VOICE; CORD; TISSUE  
Derwent Class: A96; B04; D16; D22; P32  
International Patent Class (Main): A61F-002/00  
International Patent Class (Additional): A61F-002/02; A61F-002/10;  
A61F-009/14; A61F-013/00  
File Segment: CPI; EngPI

6/5/2 (Item 2 from file: 350)

DIALOG(R)File 350:Derwent WPIX  
(c) 2003 Thomson Derwent. All rts. reserv.

012151321

WPI Acc No: 1998-568233/199848  
Related WPI Acc No: 1998-480772; 1998-506442  
XRAM Acc No: C98-170702  
XRPX Acc No: N98-442114

Augmentation and repair of dermal, subcutaneous and vocal cord tissue -  
comprises retrieving viable cells from subject, e.g. fibroblasts,  
culturing cells and placing cells at site of repair in subject

Patent Assignee: KELLER G S (KELL-I); KLEINSEK D A (KLEI-I)  
Inventor: **KELLER G S** ; **KLEINSEK D A**

Number of Countries: 080 Number of Patents: 002

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 9836704	A1	19980827	WO 98US3348	A	19980220	199848 B
AU 9866616	A	19980909	AU 9866616	A	19980220	199905

Priority Applications (No Type Date): US 983378 A 19980106; US 9737961 P 19970220

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

WO 9836704 A1 E 37 A61F-002/00

Designated States (National): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

Designated States (Regional): AT BE CH DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW

AU 9866616 A A61F-002/00 Based on patent WO 9836704

Abstract (Basic): WO 9836704 A

A method for corrective surgery in a human subject of a defect being amenable to rectification by the augmentation of tissue subadjacent to the defect, comprises: (a) retrieving viable cells (VC), e.g. fascia fibroblast, connective tissue fibroblasts, lamina propria fibroblasts and adipocyte, from the subject; (b) culturing (VC) in vitro, and (c) placing in vitro cultured (VC) into the tissue of the subject subadjacent to the defect.

Also claimed is a substantially pure in vitro produced extracellular matrix composition (EMC) produced by: (a) culturing (VC) in vitro in a culture vessel so that the (VC) produce an EMC; (b)

*the Patient*

separating the EMC produced from the culture vessel, and (c) collecting the EMC.

USE - The method and EMC is used to correct defects such as rhytid, stretch mark, wrinkle, depressed scar, cutaneous depression, hypoplasia of the lip, scarring from acne vulgaris, prominent nasolabial fold, prominent melolabial fold, post-rhinoblasty irregularity and **vocal** cord defect. The EMC are placed into the tissue of the subject by injection, engraftment, engraftment by threading and direct placement (all claimed).

Dwg.0/0

Title Terms: AUGMENT; REPAIR; DERMAL; SUBCUTANEOUS; VOICE; CORD; TISSUE; COMPRISE; RETRIEVAL; VIABLE; CELL; SUBJECT; FIBROBLAST; CULTURE; CELL; PLACE; CELL; SITE; REPAIR; SUBJECT

Derwent Class: B04; D16; P32; P42

International Patent Class (Main): A61F-002/00

International Patent Class (Additional): A61F-002/02; A61F-002/10;

A61F-009/04; A61F-013/00

File Segment: CPI; EngPI

6/5/3 (Item 3 from file: 350)

DIALOG(R)File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

012063861

WPI Acc No: 1998-480772/199841

Related WPI Acc No: 1998-506442; 1998-568233

XRAM Acc No: C98-145397

XRPX Acc No: N98-375156

**Corrective surgical enhancement for treatment of e.g. scars - using autologous or juvenile cells grown in vitro or extracellular matrix produced by such cells**

Patent Assignee: GERIGENE MEDICAL CORP. (GERI-N); KELLER G S (KELL-I); KLEINSEK D A (KLEI-I)

Inventor: **KELLER G S** ; KLEINSEK D A

Number of Countries: 080 Number of Patents: 004

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 9836705	A1	19980827	WO.98US3405	A	19980220	199841 B
AU 9866626	A	19980909	AU 9866626	A	19980220	199905
AU 740113	B	20011101	AU 9863344	A	19980220	200175
BR 9815713	A	20021105	BR 9815713	A	19980220	200279
			WO 98US3439	A	19980220	

Priority Applications (No Type Date): US 983378 A 19980106; US 9737961 P 19970220; US 983328 A 19980106

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

WO 9836705 A1 E 36 A61F-002/00

Designated States (National): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

Designated States (Regional): AT BE CH DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW

AU 9866626 A A61F-002/00 Based on patent WO 9836705

AU 740113 B A61B-019/00 Previous Publ. patent AU 9863344

BR 9815713 A A61B-019/00 Based on patent WO 9840027

Based on patent WO 9840027

Abstract (Basic): WO 9836705 A

Corrective surgery, in a human, by augmenting tissue comprises (a) collecting viable cells (fibroblasts from fascia, connective tissue or lamina propria, or adipocytes) from the subject; (b) culturing in vitro and (c) placing the cells in tissue subjacent to the defect. In a modification, the cells are from a human foetus or neonate (not restricted to cell types specified above). Also new are (1) extracellular matrix composition (A) derived from these in vitro cultures and (2) use of (A) for correcting defects instead of cells.

USE - The method is used to treat rhytids, stretch marks, wrinkles, depressed scars, cutaneous depressions, hypoplasia of the lip, prominent nasolabial or melolabial folds, scarring from acne vulgaris, post-rhinoplasty irregularity and **vocal** cord defects.

ADVANTAGE - Use of autologous or juvenile cells avoids risk associated with adverse immune responses.

Dwg.0/0

Title Terms: CORRECT; SURGICAL; ENHANCE; TREAT; SCAR; AUTOLOGOUS; JUVENILE; CELL; GROW; VITRO; EXTRACELLULAR; MATRIX; PRODUCE; CELL

Derwent Class: B04; D16; D22; P31; P32

International Patent Class (Main): A61B-019/00; A61F-002/00

International Patent Class (Additional): A61F-002/02; A61F-002/10;

A61F-009/04; A61F-013/00

File Segment: CPI; EngPI

Set	Items	Description
S1	180	AU='KELLER G'
S2	13	AU='KELLER G S'
S3	9	AU='KELLER GREGORY S'
S4	9	S1:S3 AND VOCAL
S5	9	IDPAT (sorted in duplicate/non-duplicate order)
<del>S6</del>	<del>3</del>	<del>IDPAT (primary/non-duplicate records only)</del>

? show files

File 347:JAPIO Oct 1976-2002/Dec(Updated 030402)  
(c) 2003 JPO & JAPIO

File 348:EUROPEAN PATENTS 1978-2003/Apr W03  
(c) 2003 European Patent Office

File 349:PCT FULLTEXT 1979-2002/UB=20030417,UT=20030410  
(c) 2003 WIPO/Univentio

File 350:Derwent WPIX 1963-2003/UD,UM &UP=200324  
(c) 2003 Thomson Derwent

File 371:French Patents 1961-2002/BOPI 200209  
(c) 2002 INPI. All rts. reserv.

Bib. Patents

7/5/1 (Item 1 from file: 350)  
DIALOG(R)File 350:Derwent WPIX  
(c) 2003 Thomson Derwent. All rts. reserv.

014343006 \*\*Image available\*\*  
WPI Acc No: 2002-163709/200221  
XRAM Acc No: C02-050489  
XRPX Acc No: N02-124963

**Aesthetic medical laser system for producing twin light output laser beam for skin treatment, has gain medium comprising excitable YAPNd crystal provided in resonant cavity having reflecting optic and output coupler**

Patent Assignee: LUKASHEV A (LUKA-I); TANKOVICH N (TANK-I)  
Inventor: LUKASHEV A; TANKOVICH N  
Number of Countries: 100 Number of Patents: 002  
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
US 20020002367	A1	20020103	US 2000608020	A	20000630	200221 B
			US 2001825516	A	20010403	
WO 200280800	A1	20021017	WO 2002US10481	A	20020403	200270

Priority Applications (No Type Date): US 2001825516 A 20010403; US 2000608020 A 20000630

Patent Details:

Patent No	Kind	Lan Pg	Main IPC	Filing Notes
US 20020002367	A1	12	A61B-018/20	CIP of application US 2000608020
WO 200280800	A1 E		A61B-018/22	

Designated States (National): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZM ZW

Abstract (Basic): US 20020002367 A1

NOVELTY - Aesthetic medical laser system comprises resonant cavity included with gain medium comprising excitable YAP:Nd crystal (2). Cavity has reflecting optic (6) and output coupler (4) to partially reflect light at 1079 nm and 1340 nm in proportions such that output laser beam comprises 1079 nm light and 1340 nm light having intensity ratio of I1079 to I1340, in range of 0.1-10.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

- (a) Medical treatment process using the laser system;
- (b) Process of treating the human skin

USE - For **producing** twin light output laser beam for skin treatment (claimed), microsurgery of lesions (warts, skin tags, candelomas), other pathologies (tumors, intestine and stomach polyps, **vocal cord** calcification, uterine cervix lesion ablation), hair removal, skin rejuvenation, treatment of large and small veins and blood vessels, cartilage reshaping, dermis collagen remodeling, and treatment of cancer tumors in the skin.

ADVANTAGE - The 1079 nm and 1341 nm wavelength beams illuminate the skin and heat the skin uniformly to a depth of few millimeters. The laser system caters for a large variety of laser treatments. The 1079 nm wavelength is more effective because its oxyhemoglobin absorption is 42% closer to the minimum oxyhemoglobin spike at 1100 nm. Hence the blood vessel are heated more uniformly and hair removal is performed by uniform **tissue** coagulation.

X  
Bad Date

DESCRIPTION OF DRAWING(S) - The figure shows the principle features of the laser system.

YAP:Nd crystal rod (2)

Output coupler (4)

Reflecting optic (6)

pp; 12 DwgNo 1/9

Title Terms: AESTHETIC; MEDICAL; LASER; SYSTEM; **PRODUCE** ; TWIN; LIGHT; OUTPUT; LASER; BEAM; SKIN; TREAT; GAIN; MEDIUM; COMPRISE; EXCITATION; CRYSTAL; RESONANCE; CAVITY; REFLECT; OPTICAL; OUTPUT; COUPLE  
Derwent Class: L03; P31; S05; V07; V08  
International Patent Class (Main): **A61B-018/20 ; A61B-018/22**  
File Segment: CPI; EPI; EngPI

7/5/2 (Item 2 from file: 350)

DIALOG(R)File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

012089531

WPI Acc No: 1998-506442/199843

Related WPI Acc No: 1998-480772; 1998-568233

XRAM Acc No: C98-152829

XRPX Acc No: N98-394798

**Corrective surgery of dermal, subcutaneous and vocal cord tissue defects - e.g. by placement of autologous cultured fibroblasts in locations subjacent to defect to be rectified**

Patent Assignee: GERIGENE MEDICAL CORP (GERI-N)

Inventor: KLEINSEK D A

Number of Countries: 082 Number of Patents: 006

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 9840027	A1	19980917	WO 98US3439	A	19980220	199843 B
AU 9863344	A	19980929	AU 9863344	A	19980220	199906
EP 1014880	A1	20000705	EP 98907575	A	19980220	200035
			WO 98US3439	A	19980220	
JP 2001509064	W	20010710	JP 98539578	A	19980220	200144
			WO 98US3439	A	19980220	
AU 740113	B	20011101	AU 9863344	A	19980220	200175
BR 9815713	A	20021105	BR 9815713	A	19980220	200279
			WO 98US3439	A	19980220	

*Same inventor,  
same date*

Priority Applications (No Type Date): US 983328 A 19980106; US 9737961 P 19970220

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

WO 9840027 A1 E 39 A61B-019/00

Designated States (National): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

Designated States (Regional): AT BE CH DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW

AU 9863344 A A61B-019/00 Based on patent WO 9840027

EP 1014880 A1 E A61B-019/00 Based on patent WO 9840027

Designated States (Regional): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

JP 2001509064 W 30 A61F-002/10 Based on patent WO 9840027

AU 740113 B A61B-019/00 Previous Publ. patent AU 9863344

BR 9815713 A A61B-019/00 Based on patent WO 9840027

Abstract (Basic): WO 9840027 A

The following are claimed:

(A) corrective surgery, in humans, of defects which are amenable to rectification by augmentation of **tissue** subjacent to the defect, comprising:

- (a) retrieving viable **cells** from the subject;
- (b) **culturing** the viable **cells** in vitro, and
- (c) placing a volume of the **cultured cells** into **tissue** located subjacent to the defect to be rectified;

(B) corrective surgery, in humans, of defects which are amenable to rectification by augmentation of **tissue** subjacent to the defect, comprising:

- (a) retrieving viable **cells** from the subject;
- (b) **culturing** the viable **cells** in vitro for sufficient time for the **cells** to **produce** extracellular matrix;
- (c) separating the matrix from the **culture** vessel;
- (d) collecting the matrix, and
- (e) placing the matrix into **tissue** located subjacent to the defect to be rectified;

(C) long term augmentation of subcutaneous or dermal **tissue**, in humans, comprising:

- (a) providing a suspension of autologous, passaged dermal **fibroblasts**, free of immunogenic proteins;
- (b) identifying a defect susceptible to amelioration by augmentation of the sub-adjacent subcutaneous or dermal **tissue**, and
- (c) injecting the suspension into the sub-adjacent **tissue** so that the **tissue** is augmented;

(D) in vitro-**produced** extracellular matrix composition, which is either pure or combined with **cells** embedded in the matrix, **produced** by a process comprising:

- (a) **culturing cells** in vitro in a **culture** vessel for sufficient time for the **cells** to **produce** extracellular matrix;
- (b) separating the matrix from the **culture** vessel and, if the composition is pure, separating the matrix from the **cells**, and
- (c) collecting the matrix, and

(E) a device for repairing a dermal defect in a subject, comprising:

- (a) a hypodermic syringe which has:
  - (i) a syringe chamber;
  - (ii) a piston disposed in the chamber, and
  - (iii) an orifice communicating with the chamber;
- (b) a suspension (which is disposed in the chamber) comprising:
  - (i) dermal **fibroblasts** (derived from the subject) which are free of **cells** other than **fibroblasts** and are free of proteins that are immunogenic in the subject) and
  - (ii) a carrier solution, and
  - (c) a hypodermic needle affixed to the orifice.

USE - The processes may be used for augmentation and/or repair of dermal, subcutaneous or **vocal cord tissue**. Typical skin defects include rhytids, stretch marks, depressed scars, cutaneous depressions of traumatic or non-traumatic origin, hypoplasia of the lip and/or scarring from acne vulgaris. These defects can be corrected by placement of autologous **fibroblasts** or adipocytes. Typical **vocal cord** defects include scarred, paralysed, surgically injured, traumatically injured or congenitally underdeveloped **vocal cords**. These defects can be corrected by placement of lamina propria or autologous **cultured fibroblasts** from lamina propria.

Dwg.0/0

Title Terms: CORRECT; SURGICAL; DERMAL; SUBCUTANEOUS; VOICE; CORD; **TISSUE**; DEFECT; PLACE; AUTOLOGOUS; **CULTURE**; **FIBROBLAST**; LOCATE; SUBJACENT; DEFECT; RECTIFY



Derwent Class: B04; D16; D22; P31; P32  
International Patent Class (Main): **A61B-019/00** ; A61F-002/10  
File Segment: CPI; EngPI

7/5/3 (Item 3 from file: 350)  
DIALOG(R) File 350:Derwent WPIX  
(c) 2003 Thomson Derwent. All rts. reserv.

012063861  
WPI Acc No: 1998-480772/199841  
Related WPI Acc No: 1998-506442; 1998-568233  
XRAM Acc No: C98-145397  
XRPX Acc No: N98-375156

**Corrective surgical enhancement for treatment of e.g. scars - using autologous or juvenile cells grown in vitro or extracellular matrix produced by such cells**

Patent Assignee: GERIGENE MEDICAL CORP (GERI-N); KELLER G S (KELL-I);  
KLEINSEK D A (KLEI-I)

Inventor: KELLER G S; KLEINSEK D A

Number of Countries: 080 Number of Patents: 004

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 9836705	A1	19980827	WO 98US3405	A	19980220	199841 B
AU 9866626	A	19980909	AU 9866626	A	19980220	199905
AU 740113	B	20011101	AU 9863344	A	19980220	200175
BR 9815713	A	20021105	BR 9815713	A	19980220	200279
			WO 98US3439	A	19980220	

Priority Applications (No Type Date): US 983378 A 19980106; US 9737961 P  
19970220; US 983328 A 19980106

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

WO 9836705 A1 E 36 A61F-002/00

Designated States (National): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU  
CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR  
LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM  
TR TT UA UG UZ VN YU ZW

Designated States (Regional): AT BE CH DE DK EA ES FI FR GB GH GM GR IE  
IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW

AU 9866626 A A61F-002/00 Based on patent WO 9836705

AU 740113 B A61B-019/00 Previous Publ. patent AU 9863344

Based on patent WO 9840027

BR 9815713 A A61B-019/00 Based on patent WO 9840027

Abstract (Basic): WO 9836705 A

Corrective surgery, in a human, by augmenting **tissue** comprises  
(a) collecting viable **cells** ( **fibroblasts** from fascia, connective  
**tissue** or lamina propria, or adipocytes) from the subject; (b)  
**culturing** in vitro and (c) placing the **cells** in **tissue** subjacent  
to the defect. In a modification, the **cells** are from a human foetus  
or neonate (not restricted to **cell** types specified above). Also new  
are (1) extracellular matrix composition (A) derived from these in  
vitro **cultures** and (2) use of (A) for correcting defects instead of  
**cells**.

USE - The method is used to treat rhytids, stretch marks, wrinkles,  
depressed scars, cutaneous depressions, hypoplasia of the lip,  
prominent nasolabial or melolabial folds, scarring from acne vulgaris,  
post-rhinoplasty irregularity and **vocal cord** defects.

ADVANTAGE - Use of autologous or juvenile **cells** avoids risk

*the  
patent  
(?)*

associated with adverse immune responses.

Dwg.0/0

Title Terms: CORRECT; SURGICAL; ENHANCE; TREAT; SCAR; AUTOLOGOUS; JUVENILE;  
**CELL ; GROW ; VITRO; EXTRACELLULAR; MATRIX; PRODUCE ; CELL**

Derwent Class: B04; D16; D22; P31; P32

International Patent Class (Main): **A61B-019/00** ; A61F-002/00

International Patent Class (Additional): A61F-002/02; A61F-002/10;

A61F-009/04; A61F-013/00

File Segment: CPI; EngPI

**7/5/4 (Item 4 from file: 350)**

DIALOG(R)File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

009819057

WPI Acc No: 1994-098913/199412

XRPX Acc No: N94-077264

**Plastic surgery of larynx when scar stenosis occurs - inserting rubber  
stent into larynx clearance and replacing stent by silicon tube on  
fifth-seventh day**

Patent Assignee: MOSC EAR THROAT NOSE RES INST (MOEA-R)

Inventor: LAPCHENKO S N; OGLY MAMEDOV E T

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
SU 1790923	A1	19930130	SU 4813704	A	19900227	199412 B

Priority Applications (No Type Date): SU 4813704 A 19900227

Patent Details:

Patent No	Kind	Lan Pg	Main IPC	Filing Notes
SU 1790923	A1	1	A61B-017/00	

Abstract (Basic): SU 1790923 A

The proposed method involves resection of scar **tissues** , and re-canalisation. After that, a triangular panniculus ( **tissue** layer) from arytenoid-epiglottis area is displaced to the **produced** defect.

The front surface of the larynx is separated, and shield-like cartilage and inter-larynx structures are dissected departing 2-3 mm from the middle line. Scar **tissue** is removed in the area of **vocal** and vestibular **folds** . A triangular panniculus is cut and displaced on the prepared bed, and fixed by stitches. A rubber stent is inserted into the larynx clearance. The stent is replaced by T-shaped silicon tube on fifth-seventh day and kept in the larynx until larynx clearance stable normalisation is reached.

USE/ADVANTAGE - In otorhino-laryngology. Recovery of voice function and free breathing are claimed. Bul.4/30.1.93

Dwg.0/0

Title Terms: PLASTIC; SURGICAL; LARYNX; SCAR; STENOSIS; OCCUR; INSERT;  
RUBBER; STENT; LARYNX; CLEARANCE; REPLACE; STENT; SILICON; TUBE; FIFTH;  
SEVENTH; DAY

Derwent Class: P31

International Patent Class (Main): **A61B-017/00**

File Segment: EngPI

Set	Items	Description
S1	273	VOCAL(2N) (FOLD? ? OR CORD? ? OR LIGAMENT? ?) OR PLICAE()VO-CAL??
S2	582808	FIBROBLAST? ? OR CELL? ? OR TISSUE? ?
S3	3103701	CULTUR? OR GROW??? OR CULTIVAT? OR PRODUC????
S4	23	S1 AND S2 AND S3
S5	4	S4 AND IC=A61B
S6	4	IDPAT (sorted in duplicate/non-duplicate order)
S7	4	IDPAT (primary/non-duplicate records only)

? show files

File 347:JAPIO Oct 1976-2002/Dec(Updated 030402)

(c) 2003 JPO & JAPIO

File 350:Derwent WPIX 1963-2003/UD,UM &UP=200324

(c) 2003 Thomson Derwent

File 371:French Patents 1961-2002/BOPI 200209

(c) 2002 INPI. All rts. reserv.

FT  
Patents

7/5,K/5 (Item 5 from file: 349)  
DIALOG(R) File 349:PCT FULLTEXT  
(c) 2003 WIPO/Univentio. All rts. reserv.

00979689

**BIODEGRADABLE INJECTABLE IMPLANTS AND RELATED METHODS OF MANUFACTURE AND USE**

**Patent Applicant/Assignee:**

MEDGRAFT MICROTECH INC, 1330 Post Oak Boulevard, Suite 1600, Houston, TX 77056, US, US (Residence), US (Nationality), (For all designated states except: US)

**Patent Applicant/Inventor:**

CASERES Crisofo Peralta, A.V. Mexico 201, Col. Hipodromo Condesa, Mexico City, 06100, MX, MX (Residence), MX (Nationality), (Designated only for: US)

D'LAGARDE Danel Leon, A.V. Mexico 201, Col. Hipodromo Condesa, Mexico City, 06100, MX, MX (Residence), MX (Nationality), (Designated only for: US)

**Legal Representative:**

STAFFORD Nicole (agent), Vinson & Elkins L.L.P., 2300 First City Tower, 1001 Fannin, Houston, TX 77002-6760, US,

**Patent and Priority Information (Country, Number, Date):**

Patent: WO 200307782 A2 20030130 (WO 0307782)  
Application: WO 2002US20802 20020628 (PCT/WO US0220802)  
Priority Application: MX 20016732 20010629; US 20012283 20011205

Bad  
Date

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW  
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR  
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG  
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW  
(EA) AM AZ BY KG KZ MD RU TJ TM

Main International Patent Class: **A61B**

Publication Language: English

Filing Language: English

**English Abstract**

This invention is directed to the field of medical implants, and more specifically to biodegradable injectable implants and their methods of manufacture and use. The injectable implants disclosed herein comprise glycolic acid and bio-compatible/bio-absorbable polymeric particles containing a polymer of lactic acid. The particles are small enough to be injected through a needle but large enough to avoid engulfment by macrophages. The injectables of this invention may be in a pre-activated solid form or an activated form (e.g., injectable suspension or emulsion).

**Legal Status (Type, Date, Text)**

Publication 20030130 A2 Without international search report and to be republished upon receipt of that report.

**Detailed Description**

... sutures, staples); tissue screws; orthopedic fixation devices (pins, rods, screws, tacks, ligaments); dental applications (guided tissue regeneration, such as **products** for gums and regeneration of maxillary bone); cardiovascular applications (stents, grafts); intestinal applications

(anastomosis rin...at the site of the wrinkle or scar or to treat certain conditions of the **vocal cords** or to support tendons by injection at those sites.

hus, an aspect of the invention...the pyloric or lower esophageal sphincter. The injection site may also be tissue defining a **vocal cord**.

If the ...is so infiltrated. The biocompatibility of the PLA makes it a superior support for cellular **growth** and **tissue** regeneration.

## 2 1 PLA Composition and Properties

The PLA may comprise any polymer of lactic...pyloric sphincter deficiency, such as deficiencies contributing to incontinence or acid reflux, the treatment of **vocal cord** paralysis, and the correction of congenital anomalies. The present injectables may also be used as...the deep dorsal vein 20, and the deep artery 2 1.

7/5,K/11 (Item 11 from file: 349)  
DIALOG(R)File 349:PCT FULLTEXT  
(c) 2003 WIPO/Univentio. All rts. reserv.

00519812 \*\*Image available\*\*

### SOFT TISSUE RECONSTRUCTOR AND METHOD OF USE

### DISPOSITIF DE RECONSTRUCTION DES TISSUS MOUS ET SON PROCEDE D'UTILISATION

Patent Applicant/Assignee:

REPROGENESIS INC,  
BETH ISRAEL-DEACONESS MEDICAL CENTER,  
BORLAND Kermit M,  
MARLER Jennifer,

Inventor(s):

BORLAND Kermit M,  
MARLER Jennifer,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9951164 A1 19991014

Application: WO 99US6745 19990329 (PCT/WO US9906745)

Priority Application: US 9880545 19980403

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES

FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU

LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA

UG US UZ VN YU ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ

TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI

CM GA GN GW ML MR NE SN TD TG

Main International Patent Class: A61F-002/00

International Patent Class: A61K-047/00; A61L-027/00; A61M-005/42;

**A61B-019/00**

Publication Language: English

### English Abstract

This invention is directed to methods of tissue reconstruction and kits and apparatus for the practice of the method. In the method, an injection means, which may be a hollow tube, is positioned intradermally, subdermally, or subcutaneously beneath a soft tissue defect. A tissue shaping means is positioned on top of a soft tissue defect. Conformation means is applied to conform the soft tissue defect to the shape of the tissue shaping means. Then a biocompatible material which may optionally comprise living cells is injected into a subcutaneous location to treat

*Bad  
Data*

the soft tissue defect. A soft tissue reconstructor comprising the surface shaping means, the injection means, and the conformation means is described to facilitate the practice of the method. Further, a kit, which optionally includes a biocompatible material for injection, is described.

#### Detailed Description

... of developmental defects. One example of interior soft tissue reconstruction is the reconstruction of the **vocal cords** after surgery.

... maintain their form after deposit. Materials that fit this category include those that comprise living **tissue** or material that will attract **growth** and colonization of living **tissue** into a site. Suitable materials include tissue 1 5 engineering compositions which are implantable by...to be encased in the injectable hydrogel can be obtained directly from a donor, from **cell culture** of **cells** from a donor, or from established **cell culture** lines. In the preferred embodiments, **cells** are obtained directly from a donor, washed and I 0 implanted directly in combination with...

7/5,K/13 (Item 13 from file: 349)

DIALOG(R) File 349:PCT FULLTEXT

(c) 2003 WIPO/Univentio. All rts. reserv.

00449563

#### AUGMENTATION AND REPAIR OF DERMAL, SUBCUTANEOUS, AND VOCAL CORD TISSUE DEFECTS

Patent Applicant/Assignee:

GERIGENE MEDICAL CORPORATION,

KLEINSEK Don A,

Inventor(s):

KLEINSEK Don A,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9840027 A1 19980917

Application: WO 98US3439 19980220 (PCT/WO US9803439)

Priority Application: US 9737961 19970220; US 983328 19980106

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES

FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD

MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US

UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE

CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

MR NE SN TD TG

Main International Patent Class: A61B-019/00

Publication Language: English

#### English Abstract

This invention is a methodology for the long-term augmentation, and/or repair of dermal, subcutaneous, or **vocal cord** tissue by the injection, or direct surgical placement of autologous **cultured fibroblasts** derived from connective **tissue**, or dermis, or fascia lamina propria tissue fibroblasts derived from the lamina propria or adipocytes. The **fibroblast cultures** utilized for the augmentation, and/or repair of skin defects are derived from either connective tissue, dermal, and/or fascial fibroblasts. In addition a methodology of rendering the **cultured cells** substantially free of potentially immunogenic serum derived proteins by late stage passage of the **cultured fibroblasts** lamina propria **tissue**, or adipocytes in serum free

*one of the same inventors and date*

medium in the patient's own serum.

Set	Items	Description
S1	842	VOCAL(2N)(FOLD? ? OR CORD? ? OR LIGAMENT? ?) OR PLICAE()VO-CAL??
S2	463913	FIBROBLAST? ? OR CELL? ? OR TISSUE? ?
S3	1019491	CULTUR? OR GROW??? OR CULTIVAT? OR PRODUC????
S4	46	S1 AND S2 AND S3 AND IC=A61B
S5	18	S2(5N)S3 AND S1 AND IC=A61B
S6	18	IDPAT (sorted in duplicate/non-duplicate order)
S7	18	IDPAT (primary/non-duplicate records only)

? show files

File 348:EUROPEAN PATENTS 1978-2003/Apr W03  
(c) 2003 European Patent Office

File 349:PCT FULLTEXT 1979-2002/UB=20030417,UT=20030410  
(c) 2003 WIPO/Univentio



Biblio  
NPL

7/5/19 (Item 1 from file: 6)  
DIALOG(R)File 6:NTIS  
(c) 2003 NTIS, Intl Cpyrght All Rights Res. All rts. reserv.

1943938 NTIS Accession Number: AD-A302 739/8

**Canine Vocal Fold Fibroblasts in Culture : Expression of alpha-Smooth Muscle Actin and Modulation of Elastin Synthesis**

(Rept. for 1 Feb 87-31 Jan 91)

Broadley, C. ; Gonzalez, D. A. ; Nair, R. ; Davidson, J. M.  
Vanderbilt Univ., Nashville, TN.

1991 23p

Contract No.: N00014-87-C-0146

Fibroblasts from canine **vocal fold** tissue have been isolated and maintained in **culture**. These **cells** express vimentin and  $\alpha$ -smooth muscle actin, the characteristic marker of myofibroblast differentiation. Elastin **production** by **vocal fold fibroblasts** was compared to that of skin **fibroblasts**. The effects of transforming **growth** factor-Beta and hydrocortisone on elastin **production** were examined. **Vocal fold fibroblasts** in **culture** have a high elastogenic capacity compared to skin **fibroblasts**, and their elastin **production** can be enhanced by hydrocortisone (1.3uM) and TGF-Beta (10ng/ml). We conclude that the cells within the **vocal fold** are myofibroblastic in nature, and have high elastogenic potential in vitro. We suggest that connective tissue remodeling may be a continuous process in the **vocal fold**. ?

7/5/38 (Item 2 from file: 94)  
DIALOG(R)File 94:JICST-EPlus  
(c)2003 Japan Science and Tech Corp(JST). All rts. reserv.

02665305 JICST ACCESSION NUMBER: 96A0187910 FILE SEGMENT: JICST-E  
**Basic Study of Implants for Vocal Fold Augmentation. Immunohistochemical Investigation.**

TAMURA ETSUYO (1); KITAHARA SATOSHI (1); NAKANOBOS MANABU (1); SATO MICHIIYA (1); FURUKAWA TAICHI (1); NOHARA OSAMU (1); INOUE TETSUZO (1)  
Koto(Larynx Japan), 1994, VOL.6,NO.2, PAGE.122-129, FIG.8, TBL.3, REF.32  
JOURNAL NUMBER: L0919AAO ISSN NO: 0915-6127

LANGUAGE: Japanese COUNTRY OF PUBLICATION: Japan

ABSTRACT: Injectable bovine collagen has been used for **vocal fold** augmentation in human subjects. The purpose of this study was to examine the wound healing and tissue reaction of canine **vocal folds** in which collagen was injected. Two forms of bovine collagen, cross-linked and not cross-linked, were injected into **vocal folds** of dogs; the animals were killed 9 weeks and 17 weeks after injection. Immunohistochemical study in three **growth** factors, basic **fibroblast growth** factor (bFGF), transforming **growth** factor-.BETA. (TGF-.BETA.) and platelet-derived growth factor (PDGF), was performed. Not cross-linked collagen delayed normal wound healing process and implants tended to be absorbed in a long-term. On the other hand, cross-linked collagen did not disturb the wound healing process and tended to persist in the tissue with good stability. (author abst.)

Set	Items	Description
S1	28572	VOCAL(2N) (FOLD? ? OR CORD? ? OR LIGAMENT? ?) OR PLICAE()VO-CAL??
S2	15519187	FIBROBLAST? ? OR CELL? ? OR TISSUE? ?
S3	16767896	CULTUR? OR GROW??? OR CULTIVAT? OR PRODUC????
S4	1103	S1 AND S2 AND S3
S5	85	S1(S) (S2(5N)S3) NOT PY>1997
S6	45	RD (unique items)
<del>S7</del>	<del>45</del>	<del>S6 NOT PD&gt;19970220</del>

? show files

File 2:INSPEC 1969-2003/Apr W2  
(c) 2003 Institution of Electrical Engineers

File 5:Biosis Previews(R) 1969-2003/Apr W3  
(c) 2003 BIOSIS

File 6:NTIS 1964-2003/Apr W4  
(c) 2003 NTIS, Intl Cpyrght All Rights Res

File 8:Ei Compendex(R) 1970-2003/Apr W2  
(c) 2003 Elsevier Eng. Info. Inc.

File 34:SciSearch(R) Cited Ref Sci 1990-2003/Apr W3  
(c) 2003 Inst for Sci Info

File 35:Dissertation Abs Online 1861-2003/Mar  
(c) 2003 ProQuest Info&Learning

File 65:Inside Conferences 1993-2003/Apr W3  
(c) 2003 BLDSC all rts. reserv.

File 73:EMBASE 1974-2003/Apr W3  
(c) 2003 Elsevier Science B.V.

File 94:JICST-EPlus 1985-2003/Apr W3  
(c)2003 Japan Science and Tech Corp(JST)

File 144:Pascal 1973-2003/Apr W2  
(c) 2003 INIST/CNRS

File 155:MEDLINE(R) 1966-2003/Apr W3  
(c) format only 2003 The Dialog Corp.

File 172:EMBASE Alert 2003/Apr W3  
(c) 2003 Elsevier Science B.V.

File 198:Health Devices Alerts(R) 1977-2003/Apr W4  
(c) 2003 ECRI-nonprft agncy

File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec  
(c) 1998 Inst for Sci Info

File 48:SPORTDiscus 1962-2003/Apr  
(c) 2003 Sport Information Resource Centre

File 71:ELSEVIER BIOBASE 1994-2003/Apr W3  
(c) 2003 Elsevier Science B.V.

File 91:MANTIS(TM) 1880-2002/Oct  
2002 (c) Action Potential

File 162:CAB Health 1983-2003/Mar  
(c) 2003 CAB International

File 164:Allied & Complementary Medicine 1984-2003/Apr  
(c) 2003 BLHCIS

File 467:ExtraMED(tm) 2000/Dec  
(c) 2001 Informania Ltd.


[Advanced Search](#)
[Preferences](#)
[Language Tools](#)
[Search Tips](#)


[Web](#) - [Images](#) - [Groups](#) - [Directory](#) - [News](#)

Searched the web for **vocal cord fibroblast growth implantation**. Results 1 - 10 of about 61. Search took 0.23 s

### ACell, Inc.

... **growth** factor (VEGF) and basic **fibroblast growth** factor (BFGF ... therapeutically to stimulate the **growth** of new ... tissue, urinary bladder, **vocal cord** and laryngeal ...

[www.acell.com/vet/science.html](http://www.acell.com/vet/science.html) - 8k - [Cached](#) - [Similar pages](#)

### Residency Program Information

... subglottic stenosis, **vocal cord** paralysis, laryngeal ... facial paralysis, and cochlear **implantation**. ... **Fibroblast growth** factors; Alloplastic nasal reconstruction. ...

[www.healthsystem.virginia.edu/internet/otolaryngology/resident\\_page.cfm](http://www.healthsystem.virginia.edu/internet/otolaryngology/resident_page.cfm) - 43k - [Cached](#) - [Similar pages](#)

### October 2002 Abstracts

... IMPACT OF **VOCAL CORD** PARALYSIS ON CRICOARYTENOID JOINT. ... recordings were made of the **vocal** folds at ... alpha (TGF-alpha), and basic **fibroblast growth** factor (bFGF ...

[www.annals.com/2002/Oct2002\\_abstracts.htm](http://www.annals.com/2002/Oct2002_abstracts.htm) - 44k - [Cached](#) - [Similar pages](#)

### January 2001 Abstracts

... with the known suppression of **fibroblast** proliferation by ... of the neck and a paralysis of the left **vocal cord**. ... and another child had a **growth** hormone deficiency ...

[www.annals.com/2001/Jan2001\\_abstracts.htm](http://www.annals.com/2001/Jan2001_abstracts.htm) - 45k - [Cached](#) - [Similar pages](#)

### [PDF] Adipose Tissue Engineering: The Future of Breast and Soft Tissue ...

File Format: PDF/Adobe Acrobat - [View as HTML](#)

... Stress urinary incontinence 1,500,000 **Vocal cord** insufficiency Orthotic ... the ex vivo development and **implantation** of a ... membrane and basic **fibroblast growth** factor ...

[www.txcbme.org/Publications/semsurgonc.pdf](http://www.txcbme.org/Publications/semsurgonc.pdf) - [Similar pages](#)

### References on the Administration of Antibodies Using

... Saline; BSA; CSF/CNS (high **vocal** center); bird ... >> Platelet factor 4; **Fibroblast growth** factor; Antibody ... of myelin within the hatchling chick spinal **cord**. ...

[www.alzet.com/bibliography/bib\\_pages/ab.htm](http://www.alzet.com/bibliography/bib_pages/ab.htm) - 68k - [Cached](#) - [Similar pages](#)

### References from 1996 to 2001 on the Administration of Agents to ...

... antibody-; Saline; BSA; CSF/CNS (high **vocal** center); bird ... death in the rat spinal **cord** induced by ... Delayed administration of basic **fibroblast growth** factor (bFGF ...

[www.alzet.com/bibliography/bib\\_pages/brai.htm](http://www.alzet.com/bibliography/bib_pages/brai.htm) - 80k - [Cached](#) - [Similar pages](#)

### 1999 Abstracts

... that might be needed to maintain **vocal** plasticity ... is the cell dose that a **cord** blood unit ... epidermal **growth** factor (EGF) and basic **fibroblast growth** factor (bFGF ...

[www.biology.duke.edu/undergrad/theses/1999\\_abstracts.html](http://www.biology.duke.edu/undergrad/theses/1999_abstracts.html) - 79k - [Cached](#) - [Similar pages](#)

### glossary

... **Fibroblast** Cells that give rise to connective tissue ... stem cells are found in adult bone marrow, umbilical **cord** blood, fetal ... HVC (HVC) - The High **Vocal** Center ...

[www.maclester.edu/~psych/whathap/UBNRP/StemCells/glossary.html](http://www.maclester.edu/~psych/whathap/UBNRP/StemCells/glossary.html) - 45k - [Cached](#) - [Similar pages](#)

### Wound Healing References

... in improved phonatory function of the affected **vocal cord**. ... to care of the spinal **cord**

injured patient ... Abstract: Rapid **fibroblast** ingrowth and collagen deposition ...

[www.ifess.org/Services/Consumer\\_Ed/References/Wound\\_Healing\\_Refs.htm](http://www.ifess.org/Services/Consumer_Ed/References/Wound_Healing_Refs.htm) - 101k - Apr 23, 2003 - [Cached](#) - [Similar pages](#)

Gooooooooogle ►

Result Page:    1   2   3   4   5   6   [Next](#)

vocal cord fibroblast growth impla

Google Search

[Search within results](#)

Dissatisfied with your search results? [Help us improve.](#)

[Google Home](#) - [Advertise with Us](#) - [Business Solutions](#) - [Services & Tools](#) - [Jobs, Press, & Help](#)

©2003 Google


[Advanced Search](#)
[Preferences](#)
[Language Tools](#)
[Search Tips](#)


[Web](#) - [Images](#) - [Groups](#) - [Directory](#) - [News](#)

 Searched the web for **vocal cord cells implantation**. Results **1 - 10** of about **629**. Search took **0.17** seconds.

## **Cord Cells - Answers to Your Questions About Cord Cells**

Sponsored Link

[www.viacord.com](http://www.viacord.com) **Cord Blood Info - Diseases Treated by Stem Cells & More** - Click Now

## **Surgical Rehabilitation of the Vocal Cord**

 ... and injection technique damages fat **cells**, the greater ... of the arytenoid and of the **vocal cord** itself. ... absorbable sutures (Figure 1-D). **Implantation** of silastic ...

[www.bgsm.edu/voice/surgical\\_rehab.html](http://www.bgsm.edu/voice/surgical_rehab.html) - 59k - [Cached](#) - [Similar pages](#)

## **June 1998 Abstracts**

 ... pannus formation, rheumatoid arthritis, **vocal cord** paralysis. ... WORDS — aerodynamics, endoscopy, larynx, **vocal** fold, voice ... cytoplasm of serous and mucous **cells**. ...

[www.annals.com/1998/Jun98\\_abstracts.htm](http://www.annals.com/1998/Jun98_abstracts.htm) - 29k - [Cached](#) - [Similar pages](#)

## **March 2002 Abstracts**

 ... lifetime group, corresponding to an **implantation** period of ... cell carcinoma of the true **vocal cord** successfully treated ... and ZEBRA proteins) by NPC **cells** and its ...

[www.annals.com/2002/Mar2002\\_abstracts.htm](http://www.annals.com/2002/Mar2002_abstracts.htm) - 33k - [Cached](#) - [Similar pages](#)
[\[ More results from www.annals.com \]](#)

## **Case 8--Discussion**

 ... excision of a squamous papilloma of the **vocal cord** when the ... 1 virus particle in 10 **5 cells**, may be ... viral spread than to dropping and **implantation** of fragments ...

[pathhsw5m54.ucsf.edu/case8/discussion8.html](http://pathhsw5m54.ucsf.edu/case8/discussion8.html) - 18k - [Cached](#) - [Similar pages](#)

## **The PennENT**

 ... Smyth BJ, Cosgrove D. Strial marginal **cells** play a ... consequences of diagnostic imaging for **vocal cord** paralysis ... otosclerosis in the era of cochlear **implantation**. ...

[www.uphs.upenn.edu/pennorl/public.htm](http://www.uphs.upenn.edu/pennorl/public.htm) - 11k - [Cached](#) - [Similar pages](#)

## **[PDF] Controls controls noted.**

 File Format: PDF/Adobe Acrobat - [View as HTML](#)

 ... Experiments concerning the effect of the instillation or **implantation** of cigarette ... relative frequency of atypical nuclei among true **vocal cord cells**, of men ...

[sgreports.nlm.nih.gov/NN/B/B/N/Z/\\_/nnbbnz.pdf](http://sgreports.nlm.nih.gov/NN/B/B/N/Z/_/nnbbnz.pdf) - [Similar pages](#)

## **ORL**

 ... Symposium on Pediatric Cochlear **Implantation** Antwerpen, 2000. ... and dibromedulcitol in squamous cell carcinoma **cells**. ... fixation of the **vocal cord** Lichtenberger G ...

[www.orl.hu/hu/hirek/news/kulf\\_ea.shtml](http://www.orl.hu/hu/hirek/news/kulf_ea.shtml) - 27k - [Cached](#) - [Similar pages](#)

## **RBO - Surgical Correction of Histostructural Alterations of the ...**

 ... Conclusion: Autologous fat **implantation** is an important option in ... injection may affect the fatty **cells** increasing the ... bridge of the true **vocal cord**: a report ...

[www.sborl.org.br/acervo/rev67-1\\_implantedegordura\\_usa.asp](http://www.sborl.org.br/acervo/rev67-1_implantedegordura_usa.asp) - 49k - [Cached](#) - [Similar pages](#)

## **Iridology Iris Chart**

 ... **Vocal cord**. ... the tiny cavities (follicles) containing ova, or egg **cells**, in the ... prepares



**Inventor Name Search Result**

Your Search was:

Last Name = KLEINSEK

First Name = DON

Application#	Patent#	Status	Date Filed	Title	Inventor Name
<del>60163734</del>	Not Issued	159	11/05/1999	AUGMENTATION AND REPAIR OF AGE-RELATED SOFT TISSUE DEFECTS	KLEINSEK , DON A.
<del>60037961</del>	Not Issued	159	02/20/1997	AUGMENTATION AND REPAIR OF DERMAL, SUBCUTANEOUS AND VOCAL CORD DEFECTS	KLEINSEK , DON A.
<u>10129180</u> Restricted	Not Issued	030	05/03/2002	AUGMENTATION AND REPAIR OF AGE-RELATED SOFT TISSUE DEFECTS	KLEINSEK, DONALD A.
<u>09632581</u> Mine	Not Issued	071	08/03/2000	AUGMENTATION AND REPAIR OF TISSUE DEFECTS	KLEINSEK, DON A.
<del>09309167</del>	Not Issued	120	05/10/1999	NUCLEIC-ACIDS FOR INDICATING CELLULAR AGE	KLEINSEK , DON A.
<u>09026963</u> ABN	Not Issued	161	02/20/1998	AUGMENTATION AND REPAIR OF DERMAL, SUBCUTANEOUS, AND VOCAL CORD DEFECTS	KLEINSEK , DON A.
<u>09003378</u> ABN	Not Issued	161	01/06/1998	AUGMENTATION AND REPAIR OF DERMAL, SUBCUTANEOUS, AND VOCAL CORD TISSUE DEFECTS	KLEINSEK , DON A.
<del>08253936</del>	Not Issued	161	06/03/1994	NUCLEIC ACIDS FOR INDICATING CELLULAR AGE	KLEINSEK , DON A.
<del>08173359</del>	Not Issued	161	12/23/1993	CLEAN ROOM AND CLEAN ROOM CONTAINMENT CENTER	KLEINSEK , DON A.
<del>07949605</del>	<u>5259812</u>	150	09/23/1992	CLEAN ROOM AND CLEAN ROOM CONTAINMENT CENTER	KLEINSEK , DON A.

Inventor Search Completed: No Records to Display.

<b>Search Another: Inventor</b>	<b>Last Name</b>	<b>First Name</b>	<input type="button" value="Search"/>
	<input type="text" value="kleinsek"/>	<input type="text" value="don"/>	

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

**Inventor Name Search Result**

Your Search was:

Last Name = KELLER

First Name = GREG

Application#	Patent#	Status	Date Filed	Title	Inventor Name
<del>60136457</del>	Not Issued	159	05/28/1999	METHOD OF USING AUTOLOGOUS FIBROBLASTS TO PROMOTE HEALING OF WOUNDS AND FISTULAS	KELLER , GREGORY S.
<del>60037961</del>	Not Issued	159	02/20/1997	AUGMENTATION AND REPAIR OF DERMAL, SUBCUTANEOUS AND VOCAL CORD DEFECTS	KELLER , GREGORY S.
<del>29017866</del>	Not Issued	161	01/25/1994	RE-USABLE BIRDHOUSE MOUNT	KELLER , GREGORY A.
<u>09980150</u> New	Not Issued	030	08/05/2002	METHOD OF USING AUTOLOGOUS FIBROBLASTS TO PROMOTE HEALING OF WOUNDS AND FISTULAS	KELLER, GREGORY S.
<u>09634038</u> mine	Not Issued	030	08/08/2000	AUGMENTATION AND REPAIR OF VOCAL CORD TISSUE DEFECTS.	KELLER, GREGORY S.
<del>09360708</del>	RE36903	150	07/26/1999	METHOD OF LASER COSMETIC SURGERY	KELLER , GREGORY S.
<u>09003378</u> ABN	Not Issued	161	01/06/1998	AUGMENTATION AND REPAIR OF DERMAL, SUBCUTANEOUS, AND VOCAL CORD TISSUE DEFECTS	KELLER , GREGORY S.
<del>08477333</del>	<del>5807385</del>	150	06/07/1995	METHOD OF LASER COSMETIC SURGERY	KELLER , GREGORY S.
<del>08473495</del>	<del>5505727</del>	150	06/07/1995	METHOD OF LASER COSMETIC SURGERY	KELLER , GREGORY S.
<del>08314659</del>	<del>5445634</del>	150	09/29/1994	METHOD OF LASER COSMETIC SURGERY	KELLER , GREGORY S.
<u>08278574</u>	Not Issued	161	07/21/1994	METHOD AND APPARATUS FOR TAPERING A LASER OPTICAL FIBER TO A FINE POINT	KELLER , GREGORY S.
<u>08102851</u>	<u>5370642</u>	150	08/02/1993	METHOD OF LASER COSMETIC SURGERY	KELLER , GREGORY S.
<u>07958012</u>	Not Issued	166	10/07/1992	METHOD AND APPARATUS FOR TAPERING A LASER OPTICAL FIBER TO A FINE POINT	KELLER , GREGORY S.
<u>07766638</u>	Not Issued	166	09/25/1991	METHOD OF LASER COSMETIC SURGERY	KELLER , GREGORY S.

Inventor Search Completed: No Records to Display.